


28 / EVERYDAY HEALTH

Finding Cancer Earlier

Blood-based detection, the work after a positive result, and the outcome screening must ultimately improve.

JOHN GRIFFIN, MD

REVIEW EDITION · OCTOBER 2026

Earlier is a hypothesis with consequences

Finding a signal earlier can feel like an unquestionable advantage. Screening research has to ask what happens next: whether diagnosis and treatment help, whether unnecessary investigations cause harm, and whether outcomes improve for the people offered the test.

A promising detection technology can answer one part of that question while leaving others open. Sensitivity, specificity, and a plausible biological signal do not by themselves establish a reduction in cancer deaths.

What PATHFINDER showed

PATHFINDER was a prospective cohort study of a multicancer early-detection blood test in adults aged 50 or older without symptoms of cancer. Among 6,621 participants with analyzable results, 92 had a cancer signal. Cancer was diagnosed in 35 of those participants; 57 had no cancer diagnosis. [1]

The study also followed the diagnostic work prompted by the result. That is an essential part of evaluating screening. It was a feasibility study, not a randomized demonstration that offering the test improves survival.

The person lives through the uncertainty

A positive result starts a period of investigation. A negative result can also be misinterpreted if it is taken to rule out every cancer. The relevant evidence includes the whole pathway: time to resolution, imaging, procedures, complications, and whether the eventual diagnosis changes care usefully.

Lead-time bias is another concern. Counting survival from an earlier diagnosis can lengthen the measured interval even if the time of death is unchanged. A screening program therefore needs outcomes that address the benefit it promises.

A clearer decision

Before adding a test, a clinical conversation should identify the purpose, the expected follow-up, the limits of reassurance, and how it fits with established screening and individual risk. Symptoms require their own assessment; a screening test is not a substitute.

The promise of earlier detection is real enough to test rigorously. The strongest future result will connect a technically impressive signal to a demonstrable improvement in people's lives, with the burden of false alarms and unnecessary treatment included in the account.

SOURCES & READING SCOPE

Keep the claim beside its evidence

1. Deb Schrag, Tomasz M Beer, Charles H McDonnell, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet (London, England). 2023 Oct 07;402(10409):1251-1260. doi:10.1016/S0140-6736(23)01700-2. PMID:37805216. Open source →

Selected primary publication records and abstracts checked 25–26 October 2026. This is a focused reading companion, not a systematic review, a treatment protocol, or a complete appraisal of methods, supplements and later evidence.

KEEP FOLLOWING THE IDEA

Part of a connected collection

Return to a subject, follow a related booklet, or explore the wider projects. These links organize reading; they do not imply that one scientific finding proves another.

This booklet online →

Booklet directory · all 48 →

Atlas · Multi-cancer early detection blood tests →

Arising Health website →

The Arising book →

The Long Game →

Listen & watch →

Related booklets

06 · When Medicines Become Instructions →

37 · The Ancestor's Genes and What They're Becoming →

39 · The Study That Would Change My Mind →

The online review collection is hosted in the shared Atlas. Its existing access settings apply. The public website remains a separate destination.